`
The global Tumor Ablation Market is growing as healthcare providers increasingly adopt minimally invasive approaches for treating localized tumors. Tumor ablation uses technologies such as radiofrequency, microwave, cryoablation, and high-intensity focused ultrasound to destroy tumor tissue while potentially reducing recovery time, pain, and hospital stay compared with some conventional surgical approaches. Rising cancer incidence, increasing use of image-guided procedures, and technological advances in ablation systems are supporting market growth.
According to Fortune Business Insights, the global tumor ablation market was valued at USD 846.8 million in 2025 and is projected to grow from USD 903.3 million in 2026 to USD 1,579.7 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.
Why is the Tumor Ablation Market Growing?
The increasing prevalence of cancer and other chronic conditions is a major factor driving demand for tumor ablation procedures. Patients with localized tumors, as well as some patients who may not be ideal candidates for major surgery, can be treated with minimally invasive ablation approaches.
Tumor ablation is increasingly used in:
- Liver cancer
- Lung cancer
- Kidney cancer
- Bone tumors
- Localized solid tumors
- Recurrent tumors
- Patients requiring minimally invasive treatment
The advantages associated with ablation, including shorter recovery periods, reduced pain, and shorter hospital stays, are further supporting adoption.
Key Market Trends Shaping Industry Growth
Increasing Adoption of Microwave Ablation
The Microwave Ablation segment dominated the market in 2025 and is expected to account for 34.9% of the market in 2026. Increasing procedure volumes and continued product development are supporting the segment.
In January 2024, Hygea (Beijing) Medical Technology Co., Ltd. received U.S. FDA approval for its EXCEED microwave treatment system and EXACT series microwave ablation probes, supporting the expansion of microwave-based treatment technologies.
Growing Use of Percutaneous Procedures
The Percutaneous treatment segment held a dominant 68.1% share in 2025. The growth is supported by increasing use of minimally invasive procedures for cancers such as lung and liver cancer.
Percutaneous ablation can be performed using image guidance, allowing physicians to target tumors through small access points rather than requiring extensive surgical intervention.
Increasing Demand for Image-Guided Ablation
Integration of ablation systems with imaging technologies such as CT, MRI, and ultrasound is improving tumor targeting and procedural precision.
The market is increasingly moving toward systems that combine energy delivery with advanced imaging and real-time treatment planning.
Growing Adoption of Minimally Invasive Cancer Treatment
The shift toward less-invasive cancer procedures is becoming increasingly important. Patients and healthcare providers are seeking approaches that can potentially reduce recovery time, postoperative discomfort, and hospital resource use.
Increasing Product Launches and Approvals
Product development and regulatory approvals are supporting competition and technology adoption. For example, Varian launched its next-generation IntelliBlate microwave ablation solution in Europe in July 2025 for soft-tumor treatment.
Growing Interest in Advanced Non-Thermal Technologies
Emerging technologies such as histotripsy and irreversible electroporation are expanding the range of tumor-ablation approaches. These technologies are attracting attention because they use mechanisms different from conventional thermal ablation.
Market Dynamics
Driver: Increasing Prevalence of Cancer
Rising cancer incidence is a major market driver. Fortune Business Insights cites World Health Organization data indicating approximately 20 million new cancer cases globally in 2022. An aging population is also increasing the burden of chronic conditions and cancer.
Increasing numbers of patients with localized tumors or those who are medically unsuitable for major surgery are supporting demand for minimally invasive ablation approaches.
Restraint: High Costs of Advanced Products and Procedures
The high cost of advanced ablation devices and procedures can restrict adoption, particularly in developing markets. Advanced disposable probes, imaging integration, and newer technologies can increase procedure costs.
The need for multimodality imaging such as MRI and CT can further increase costs, while limited reimbursement and shortages of specialized interventional radiologists can limit adoption in some healthcare systems.
Opportunity: Technological Advancements in Ablation Systems
Technological innovation represents a major opportunity. Imaging integration, automation, and improved energy delivery are enhancing procedural precision and treatment outcomes.
Companies are also seeking regulatory approvals for novel technologies, which is expected to broaden clinical adoption and expand the range of cancers treatable using ablation systems.
Challenge: Specialized Infrastructure and Reimbursement
Tumor ablation often requires advanced imaging infrastructure, specialized equipment, trained interventional radiologists, and dedicated hospital resources. Limited reimbursement for newer technologies can slow adoption even when clinical interest is strong.
For detailed market insights: https://www.fortunebusinessinsights.com/tumor-ablation-market-114842
Market Segmentation Analysis
By Product Type
Accessories Segment Dominates
The Accessories segment accounted for the largest share of the market in 2025. Growth is being supported by increasing ablation procedure volumes and recurring demand for procedure-related products.
The increasing focus of manufacturers on launching innovative accessories and supporting products is expected to contribute to continued segment growth.
Instruments Segment
The Instruments segment is expected to grow at a CAGR of 7.2% during the forecast period. This segment includes the core ablation equipment used to deliver energy and perform tumor destruction.
By Technology
Microwave Ablation Segment Dominates
The Microwave Ablation segment dominated the market in 2025 and is expected to hold a 34.9% share in 2026. Increasing procedure volumes and the focus of major players on regulatory approvals are supporting market expansion.
Radiofrequency Ablation
Radiofrequency ablation remains an established technology for treating localized tumors and continues to be used across several clinical applications.
Cryoablation
Cryoablation destroys tumor tissue through controlled freezing. It is increasingly used in selected liver, kidney, and other tumor applications.
High-Intensity Focused Ultrasound
The High-Intensity Focused Ultrasound segment is expected to grow at a CAGR of 9.6%, making it one of the faster-growing technologies in the market.
Other Technologies
The category includes newer and emerging approaches such as non-thermal ablation technologies, which are being investigated and commercialized for specific tumor applications.
By Treatment Type
Percutaneous Segment Dominates
The Percutaneous segment accounted for 68.1% of the market in 2025. Rising cancer prevalence and growing use of minimally invasive tumor procedures are key factors supporting the segment.
Fortune Business Insights cites U.S. data showing that the number of percutaneous ablation procedures increased from 2,539 to 4,571 between the referenced study periods.
Surgical Segment
The Surgical segment is expected to grow at a CAGR of 6.3% through the forecast period.
Surgical ablation remains relevant when tumor characteristics or anatomical considerations require treatment within a surgical setting.
Laparoscopic Segment
Laparoscopic approaches offer a less invasive alternative to open surgery and are used in selected tumor-treatment procedures where appropriate.
By Application
Liver Cancer Segment Dominates
The Liver Cancer segment accounted for 40.0% of the global market in 2025, making it the leading application. Increasing prevalence of liver cancer is supporting demand for ablation technologies.
Fortune Business Insights cites 2022 data indicating approximately 367,657 new liver cancer cases in China, highlighting the significant patient population in major markets.
Lung Cancer
Lung cancer represents an important application because image-guided percutaneous ablation can be used for selected localized tumors and patients who may not be suitable for certain surgical procedures.
Kidney Cancer
The Kidney Cancer segment is expected to grow at a CAGR of 6.7% during the forecast period.
Growing use of minimally invasive renal tumor treatments is supporting demand.
Other Applications
Other applications include selected bone tumors and additional localized solid tumors where ablation may be considered as part of a multidisciplinary treatment strategy.
By End User
Hospitals & Clinics Segment Dominates
The Hospitals & Clinics segment dominated the market in 2025 and is expected to hold a 67.2% share in 2026. Growing cancer prevalence, increasing ablation procedure volumes, and expansion of hospital infrastructure are supporting the segment.
Cancer Care Centers
Cancer care centers are increasingly investing in specialized minimally invasive treatment capabilities. This segment is projected to grow at a CAGR of 7.7% during the study period.
Other End Users
Other users include specialty facilities and healthcare organizations implementing image-guided interventional oncology technologies.
Regional Insights
North America Leads the Global Market
North America generated USD 341.3 million in 2025, representing a 40.3% share of the global market. Strong healthcare infrastructure, increasing cancer prevalence, high procedure volumes, reimbursement availability, and product launches are supporting the region's leadership.
The U.S. market is estimated to reach USD 328.4 million in 2026.
Europe
Europe is projected to reach USD 287.8 million in 2026 and is expected to grow at a CAGR of 7.1% during the forecast period. Increasing cancer prevalence, adoption of minimally invasive procedures, access to advanced tumor therapies, and improving healthcare infrastructure are supporting regional growth.
The U.K. is expected to reach USD 43.7 million, Germany USD 54.1 million, and France USD 43.9 million in 2026.
Asia Pacific
Asia Pacific is expected to reach USD 203.3 million in 2026, supported by expanding interventional-radiology capabilities and increasing adoption of minimally invasive tumor treatment.
China is estimated to reach USD 96.7 million, while India is estimated to reach USD 22.3 million in 2026.
Latin America
The Latin America market is expected to reach USD 29.9 million in 2026. Growing cancer prevalence, improvements in healthcare infrastructure, and increasing adoption of radiofrequency and microwave ablation are supporting regional development.
Middle East & Africa
The GCC market is expected to reach USD 9.7 million in 2026. Increasing healthcare investment and adoption of advanced cancer-treatment technologies are supporting gradual market expansion.
Competitive Landscape
The global Tumor Ablation Market is competitive, with major medical-device companies focusing on microwave ablation, laser ablation, radiofrequency ablation, cryoablation, image-guided procedures, and non-thermal ablation technologies. Medtronic, Johnson & Johnson Services, Inc., and Boston Scientific Corporation were prominent players in the market in 2025. Companies are also strengthening their positions through product launches, acquisitions, collaborations, and technology integration.
Major Companies Operating in the Market
- Medtronic
- Johnson & Johnson Services, Inc.
- Boston Scientific Corporation
- AngioDynamics
- Abbott
- Focal One
- Hologic, Inc.
- Stryker
- Olympus Corporation
- Siemens Healthineers AG
The current Fortune Business Insights public report does not disclose individual company market-share percentages, so unsupported company-share figures are not included.
Investment Analysis and Opportunities
The Tumor Ablation Market is attracting investment as healthcare providers increasingly shift toward minimally invasive cancer-treatment approaches. Investment is particularly focused on image-guided ablation, advanced energy-delivery systems, robotic assistance, and technologies designed to improve treatment precision.
Key Investment Opportunities
- Microwave ablation systems
- Image-guided tumor ablation
- Laser ablation technologies
- Cryoablation
- Histotripsy
- Irreversible electroporation
- AI-assisted treatment planning
- Robotic-assisted ablation
- MRI-guided procedures
- CT- and ultrasound-guided systems
- Integrated ablation and immunotherapy approaches
The increasing use of CT, MRI, and ultrasound guidance, along with automation and data analytics, is creating additional opportunities for technology developers.
New Product Development
Product development in the Tumor Ablation Market is increasingly focused on improving targeting precision, treatment monitoring, energy delivery, and minimally invasive performance.
Key development areas include:
- Next-generation microwave ablation systems
- MRI-guided laser ablation
- AI-assisted tumor targeting
- Advanced cryoablation systems
- Image-guided thermal monitoring
- Histotripsy systems
- Irreversible electroporation platforms
- Robotic-assisted ablation
- Multi-modality imaging integration
- Smart ablation probes
The market is increasingly moving toward technologies that combine ablation energy with real-time imaging, automation, and data analytics to improve procedural precision and treatment outcomes.
Five Recent Industry Developments
According to Fortune Business Insights, notable recent developments include:
- October 2025: Medtronic collaborated with Techsomed Ltd. to combine Techsomed's BioTraceIO360 software with Medtronic's Emprint microwave ablation system for image-guided ablation therapy.
- June 2025: Medtronic received U.S. FDA approval for its Visualase V2 MRI-Guided Laser Ablation System, providing a minimally invasive option for patients with focal epilepsy, brain tumors, and radiation necrosis.
- October 2024: AngioDynamics partnered with University College London Hospital for a multicenter prospective study evaluating the long-term effects of the NanoKnife System in men with unifocal intermediate-risk prostate cancer.
- March 2024: Clinical Laserthermia Systems Americas announced that ROSE Urology initiated use of the TRANBERG Thermal Therapy System for prostate cancer treatment.
- March 2021: Avenda Health received U.S. breakthrough device designation for its Avenda Health Focal Therapy System.
Request Sample Report
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/tumor-ablation-market-114842
Future Outlook
According to Fortune Business Insights, the global Tumor Ablation Market was valued at USD 846.8 million in 2025 and is projected to grow from USD 903.3 million in 2026 to USD 1,579.7 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.
Increasing Adoption of Minimally Invasive Cancer Treatment
The shift toward minimally invasive treatments is expected to remain a key growth driver. Reduced trauma, shorter hospital stays, faster recovery, and potentially lower postoperative burden are encouraging the use of ablation for selected tumors.
Growth of Microwave Ablation
The Microwave Ablation segment is expected to remain the leading technology, with a projected 34.9% share in 2026. Growing procedure volumes and increasing product approvals are supporting segment expansion.
Expansion of High-Intensity Focused Ultrasound
The High-Intensity Focused Ultrasound segment is projected to grow at a CAGR of 9.6% during the forecast period, making it one of the faster-growing technology categories.
Increasing Use of Percutaneous Procedures
The Percutaneous segment accounted for 68.1% of the market in 2025 and is expected to remain dominant. Increasing use of minimally invasive treatment for cancers such as liver and lung cancer is supporting this segment.
Growing Demand for Liver Cancer Treatment
The Liver Cancer segment accounted for 40.0% of the global market in 2025. The increasing burden of liver cancer and growing use of ablation for localized tumors are expected to support continued demand.
Increasing Adoption of Image-Guided Ablation
The integration of CT, MRI, and ultrasound with ablation systems is expected to remain an important growth trend. Real-time imaging can help clinicians improve tumor targeting and procedural precision.
Growing Role of AI and Data Analytics
AI and data analytics are increasingly being integrated into tumor-ablation workflows. These technologies can support treatment planning, image interpretation, monitoring, and procedural decision-making.
Expansion of Non-Thermal Technologies
Emerging approaches such as histotripsy and irreversible electroporation are expanding the range of ablation technologies available for selected tumor applications. Regulatory approvals and clinical adoption of these approaches could create additional market opportunities.
Growth of Combination Therapies
Ablation is increasingly being explored alongside immunotherapy and targeted drug therapies, creating opportunities for combination-treatment strategies in oncology.
Regional Growth Opportunities
North America dominated the global market with a 40.3% share in 2025, while Europe and Asia Pacific are expected to show considerable growth during the forecast period.
North America
North America generated USD 341.3 million in 2025. Strong healthcare infrastructure, cancer-treatment capacity, reimbursement availability, increasing ablation volumes, and frequent product launches are supporting regional leadership. The U.S. market is estimated to reach USD 328.4 million in 2026.
Europe
Europe is projected to reach USD 287.8 million in 2026, growing at a CAGR of 7.1%. Increasing cancer prevalence, broader use of minimally invasive procedures, and improving access to advanced tumor therapies are supporting growth. Germany is projected to reach USD 54.1 million, while the U.K. is projected to reach USD 43.7 million in 2026.
Asia Pacific
Asia Pacific is projected to reach USD 203.3 million in 2026 and remains an important growth region as interventional-radiology capabilities expand. China is estimated at USD 96.7 million, while India is estimated at USD 22.3 million in 2026.
Latin America
The Latin America market is projected to reach USD 29.9 million in 2026. Increasing cancer prevalence, healthcare-infrastructure development, and adoption of radiofrequency and microwave ablation are supporting regional demand.
Middle East & Africa
The GCC market is projected to reach USD 9.7 million in 2026. Increasing healthcare investment and adoption of advanced cancer-treatment technologies are creating opportunities in the region.
Overall, microwave ablation, percutaneous procedures, image-guided treatment, AI-assisted technologies, high-intensity focused ultrasound, non-thermal ablation, and combination oncology therapies are expected to remain the major growth areas for the global Tumor Ablation Market through 2034.
What’s Driving Japan’s Market? Discover the Latest Tumor Ablation Market Insights
`
Top comments (0)